

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection

Ming-Chao Tsai (✉ tony0779@gmail.com)

Chang Gung Memorial Hospital Kaohsiung Branch <https://orcid.org/0000-0002-3613-2051>

Yi-Hao Yen

Chang Gung Memorial Hospital Kaohsiung Branch

Kuo-Chin Chang

Chang Gung Memorial Hospital Kaohsiung Branch

Chao-Hung Hung

Chang Gung Memorial Hospital Kaohsiung Branch

Chien-Hung Chen

Chang Gung Memorial Hospital Kaohsiung Branch

Ming-Tsung Lin

Chang Gung Memorial Hospital Kaohsiung Branch

Tsung-Hui Hu

Chang Gung Memorial Hospital Kaohsiung Branch

Research article

Keywords: uPA, Hepatocellular carcinoma, liver resection

Posted Date: September 25th, 2019

DOI: <https://doi.org/10.21203/rs.2.14761/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on December 2nd, 2019. See the published version at <https://doi.org/10.1186/s12885-019-6397-3>.

Abstract

Background Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease that is involved in the invasiveness and progression of cancer. There is good evidence that uPA expression is a clinically relevant biomarker in some solid tumors, but its role in hepatocellular carcinoma (HCC) is uncertain. We evaluated the prognostic value of serum uPA before surgery in HCC patients receiving curative resection. **Methods** Serum uPA levels were determined by enzyme-linked immunosorbent assay in 282 HCC patients who received complete liver resections at Kaohsiung Chang Gung Memorial Hospital. Overall survival (OS) curves were constructed using the Kaplan-Meier method and compared using the log-rank test. A Cox proportional -hazards regression model was used to identify independent prognostic factors. The median follow-up time was 52 months. **Results** Patients with higher pretreatment serum uPA (≥ 1 ng/ml) had significantly shorter OS ($p = 0.002$). Patients with liver cirrhosis, hypoalbuminemia, and thrombocytopenia were significantly more likely to present with elevated uPA levels. Multivariate Cox regression analyses indicated that high pretreatment serum uPA [hazard ratio (HR), 1.848, $p = 0.006$], vascular invasion (HR, 2.940, $p < 0.001$), and pathology stage III/IV (HR, 3.517, $p < 0.001$) were independent prognostic factors for OS. In further stratified analyses, the combination of serum uPA and AFP had more capacity to predict OS. **Conclusions** We conclude that uPA is a clinically relevant biomarker in HCC patients receiving curative resection, with higher expression of uPA being associated with higher mortality. This also highlights the potential utility of uPA as a therapeutic target for improved treatment strategies.

Background

Hepatocellular carcinoma (HCC) is ranked as the second most common cause of cancer-related death worldwide and the fifth most frequent malignancy according to global cancer statistics [[1, 2]]. It is often considered to be linked to multiple risk factors, such as infections with hepatitis B virus (HBV) and hepatitis C virus (HCV), metabolic syndrome, and alcohol abuse [[3]]. The incidence of HCC has increased over the past decade, and it typically arises in the setting of liver cirrhosis. There is a wide variety of therapeutic options for patients with HCC, depending on liver function, performance status, and tumor burden [[4]]. To date, curative hepatic resection remains the most effective treatment for patients with HCC, especially in countries with a scarcity of donor organs [[1]]. However, the overall survival (OS) remains unsatisfactory.

Recent studies have shown that several parameters are independent predictors of survival after curative resection, such as tumor size, vascular invasion, resection margin status, and pathology stage [[5]]. Most of these factors are determined only after surgery and are not satisfactory in clinical practice for the prediction of outcomes. As a result, it is desirable to obtain simple serum biochemical markers that can be easily obtained at outpatient clinics before surgery to improve prognosis by allowing earlier intervention.

The urokinase-plasminogen activator (uPA) system comprises uPA, its receptor uPAR, and two inhibitors, PAI-1 and PAI-2. The system has a defined role in tissue degradation and extravascular fibrinolysis, and it is responsible for most of the activated plasminogen associated with cancer invasion and metastasis [[6]]. Furthermore, uPA is a member of the plasminogen activator system and a key serine protease that is involved in the conversion of inactive plasminogen into active plasmin, which in turn functions in a range of events of the metastatic cascade [[7]]. Many studies have shown that uPA overexpression is associated with a worse prognosis in many cancers, including breast cancer, lung cancer, and ovarian cancer [[8-11]]. However, only one study has been conducted for HCC patients so far [[12]]. Zheng et al. showed that the concomitant overexpression of uPA and its receptor uPAR correlate with HCC invasiveness and metastasis.

As uPA can be shed from tumor stroma into the blood vessels, the potential use of circulating uPA in serum has been first explored in the late 1980s. Since then, many studies have found higher serum uPA levels in cancer patients than in healthy individuals [[13]]. However, there have been no studies that have investigated serum uPA in HCC patients. Hence, we conducted this study to test the hypothesis that elevated serum uPA in pretreatment serum samples predict poor prognosis in HCC patients undergoing curative resection.

Methods

Patients and follow-up

From January 2006 to April 2015, 287 patients who underwent curative hepatic resection for HCC at Kaohsiung Chang Gung Memorial Hospital were recruited into this study. The diagnosis of HCC was confirmed histologically based on tumor resection. All patients were followed up in the outpatient clinic with regular surveillance for recurrence by serum AFPs level and ultrasound every 3 months or contrast-enhanced CT or MRI scans if recurrent HCC was suspected. All patients were followed up until death or December 2017. The demographics, clinical characteristics, and pathological findings of HCC were recorded.

OS was defined as the interval between the dates of surgery and death due to any cause or the interval between surgery and the last observation. Disease-free survival (DFS) denotes the chances of remaining free of disease after hepatic resection for patients with HCC according to liver CT or MRI studies. This study complies with the standards of the Declaration of Helsinki and current ethical guidelines and was approved by the Institutional Review Board of Chang Gung Memorial Hospital. A waiver of consent was obtained, and patient records/information were anonymized and de-identified prior to analysis.

Sample collection and assay of serum uPA level

Serum samples were collected from TissueBank and BioBank at Kaohsiung Chang Gung Memorial Hospital. The samples had been collected before the hepatic resection and were stored at -80°C. The serum levels of uPA were assessed using independent sandwich enzyme-linked immunosorbent assay

(ELISA) kits (GB BioFibroScore® FibA kits, General Biologicals Corporation, Hsinchu, Taiwan). The analytes were recognized by antibodies coated on the ELISA plate and horseradish peroxidase (HRP)-conjugated 2nd antibody.

Stop solution was added to each well, and the optic density (OD) value (450 nm) was measured by an ELISA reader (Emax, Molecular Devices, Sunnyvale, CA, USA). The serum level of each specimen was calculated by interpolation with quantitative standards. A total of 120 µL of archived serum sample was thawed to assess the uPA. The sensitivity of the assay for uPA was 10 ug/L, and the intra-assay and inter-assay coefficient variations of the uPA ELISA kit were <3.6% and <3.7%, respectively .

Statistical analysis

Statistical analyses were performed using SPSS software version 21 (Chicago, IL, USA). The experimental values of continuous variables are expressed as the mean ± standard error of the mean. The chi-squared test was used as appropriate to evaluate the significance of differences in data between groups. DFS and OS were determined using the Kaplan-Meier method, and comparisons were made using the log-rank test .

Independent risk factors for DFS and OS were identified through a Cox regression analysis. Potential risk factors with a P-value < 0.3 in the univariate analysis were included in the multivariate analysis. The area under the receiver operating characteristic curve (AUROC) was used to estimate the predictive accuracy of uPA and AFP. The uPA value with the highest Youden's index (sensitivity + specificity -1) yielded by the ROC analysis of diagnostic accuracies for OS was selected as the best cutoff value. A p value of <0.05 was considered statistically significant.

Results

Patient characteristics

The clinical-pathological data of the 287 HCC patients who underwent curative resection are summarized in Table 1. There were 232 males (80.8%) and 55 females (19.2%), and the mean age was 60 years (range: 29-84 years). The etiology for HCC was hepatitis B virus (HBV) in 140 patients, hepatitis C virus (HCV) in 85 patients, coinfection with both hepatitis viruses in 21 patients, and unknown in 41 patients. The mean diameter of largest tumor was 4.6 cm (range 1-9.5 cm). Pathological findings revealed vascular invasion (microvessel or macrovessel invasion) in 160 patients. The mean follow-up time was 52 months (range 1-83.8 months). Recurrence occurred in 142 patients (49.5%), whereas 87 patients (30.3%) died during follow-up.

ROC curves of serum uPA for HCC OS

Levels of serum uPA were measured in 287 patients, and the median concentration was 0.7 ng/ml (mean 1.0 ng/ml, range 0.2 – 14.7 ng/ml, standard deviation 1.36 ng/ml). ROC curve analyses were performed to evaluate the predictive accuracy of serum uPA for HCC OS, which indicated that elevated

uPA could predict HCC OS with significantly more accuracy. The optimal cut-off point was 1.0 ng/ml, which corresponded to the maximum joint sensitivity and specificity on the ROC plot for uPA (AUROC = 0.612, 95% CI = 0.539 – 0.648, $p = 0.003$).

A sensitivity of 41% and specificity of 77.5% were obtained for the prediction of death. When using this value, 28% of the patients had high uPA levels (≥ 1 ng/ml). The Kaplan-Meier estimates of DFS and OS stratified by serum uPA were dichotomized (≥ 1 ng/ml and < 1 ng/ml) and are shown in Figure 1. Patients with high serum uPA had significantly shorter OS than those with low serum uPA ($p = 0.002$), but this was not in DFS ($p = 0.192$).

Relationship between clinicopathological features and uPA levels

The clinicopathological features of HCC patients with different uPA status are summarized in Table 2. High serum uPA was associated with hypoalbuminemia ($p < 0.001$), thrombocytopenia ($p = 0.032$), and liver cirrhosis ($p < 0.001$), but not with other characteristics such as gender, age, etiology, AFP, tumor size, vascular invasion, and pathological stage.

Univariate and multivariate analyses of independent risk factors

There were 87 patients (30.3%) who died after a mean follow-up time of 52 months. The univariate analyses demonstrated that AFP ≥ 200 ng/ml (hazard ratio [HR], 2.012; 95% CI, 1.088 - 3.143; $p = 0.002$), uPA ≥ 1 ng/ml (HR, 1.968; 95% CI, 1.271 - 3.049; $p = 0.002$), tumor size > 5 cm (HR, 2.402; 95% CI, 1.515 - 3.663; $p < 0.001$), vascular invasion (HR, 3.812; 95% CI, 2.268 - 6.407; $p < 0.001$), and pathology stage (III/IV vs. I/II) (HR, 4.980; 95% CI, 3.226 - 7.687; $p < 0.001$) were associated with OS. All significant covariates in the univariate analyses were entered into a multivariate Cox analysis. Serum uPA (HR, 1.848; 95% CI, 1.191 - 2.869; $p = 0.006$), vascular invasion (HR, 2.914; 95% CI, 1.640 - 5.178; $p < 0.001$), and pathology stage (HR, 3.546; 95% CI, 2.227 - 5.648; $p < 0.001$) emerged as independent prognostic factors for OS (Table 3).

Prognostic value of serum uPA based on AFP levels

Since the univariate analysis indicated that preoperative AFP ≥ 200 ng/ml was a predictor of poor OS, we examined whether the prognostic value of serum uPA varied with the AFP level. When serum uPA and AFP were considered together, the patients were divided into four groups based on the following: uPA ≥ 1 ng/ml and AFP ≥ 200 ng/ml ($n = 24$); uPA < 1 ng/ml and AFP ≥ 200 ng/ml ($n = 42$); uPA ≥ 1 ng/ml and AFP < 200 ng/ml ($n = 57$); and uPA < 1 ng/ml and AFP < 200 ng/ml ($n = 164$). Figure 2 shows that the OS rates were significantly higher in patients with uPA < 1 ng/ml and AFP < 200 ng/ml compared with other groups ($p < 0.001$).

Discussion

This is the first study of serum uPA levels in HCC patients. We found that HCC patients with high pre-operative uPA (serum uPA ≥ 1 ng/ml) exhibited lower OS rates after curative hepatic resection surgery.

Furthermore, the combination of serum uPA and AFP could also be important in determining postoperative outcomes in response to the surgical procedure. These results may not only assist surgeons in predicting HCC patient survival but remind clinical physicians to perform timely adjuvant treatments to improve the prognosis of patients with high preoperative serum levels of uPA.

Many studies have investigated the clinical impact of the expression of members of the uPA system and their correlation with prognosis in a wide variety of cancers [[8]]. However, only one study has been conducted for HCC patients so far [[12]]. In 2000, Zheng et al. found that increasing uPA protein levels in HCC tissue was associated with increased invasion and metastasis in 22 HCC patients [[12]]. Nevertheless, commercially available tests are not extensively used because they require a great amount of fresh-frozen tissue or formalin-fixed paraffin-embedded samples.

Aside from detection in the tissue, uPA can be shed by stromal cells or tumor cells into the bloodstream and measured in serum or plasma. Many studies have indicated that serum uPA can be used to predict the outcomes of cancer patients, although conflicting results have been reported, and none of the studies have been conducted with HCC patients [[14-18]]. In the current study, we found that elevated serum uPA levels were related to poorer OS in HCC patients undergoing resection, regardless of whether it is evaluated dichotomously ($p = 0.002$) or continuously ($p = 0.005$).

The multivariate Cox regression analysis indicated that elevated serum uPA was an independent prognostic factor for OS in HCC patients ($p = 0.006$). These results are consistent with those obtained with other cancers, including prostate cancer [[19]] and gastrointestinal cancer [[20]]. Recently, Wei et al. showed that SPINK13, a suppressor of the proliferation of HCC cells, directly interacted with uPA, inhibited the cleavage of MMP9 by uPA, and achieved antitumor activity on HCC cells [[21]]. Future clinical studies are required to verify whether high serum uPA might be useful for identifying HCC patients who are most likely to benefit from SPINK13, and trials for adjuvant treatment after resection are being planned.

AFP is the most useful and cost-effect serum biomarker to evaluate the prognosis of AFP-positive HCC patients in clinical practice. However, in the present study, AFP was not an independent predictive factor for OS. To consider the impact of serum AFP on OS as much as possible, serum uPA and AFP were considered together. We found that the OS rates were significantly poorer in those with high uPA and AFP than in other groups. This demonstrated that the combination of serum uPA and AFP had more capacity to predict patients' outcomes. Importantly, in subgroups with low or high AFP levels, serum uPA still had the ability to discriminate HCC patients undergoing curative resection with good prognoses from those with poor OS. More studies are required to validate the clinical role in different types of management, such as radiofrequency ablation (RFA) or transcatheter arterial chemoembolization (TACE).

We found that serum uPA was significantly elevated in HCC patients with liver cirrhosis, hypoalbuminemia, and thrombocytopenia, which provides additional evidence that elevated serum uPA may play a role in the prediction of liver fibrosis severity. Hepatic fibrosis is characterized by the progressive deposition of extracellular matrix (ECM) in patients with chronic liver injury. Hepatic stellate

cells (HSCs) are the major source of ECM in the liver. They are also the primary cellular mediator of hepatic fibrosis through their transdifferentiation, or activation from a vitamin A-storing cell to a contractile, matrix-producing myofibroblast in response to liver injury and inflammation [[22, 23]]. TGF- β triggers the uPA pathway, which activates quiescent HSCs and causes ECM deposition [[24]]. Hence, uPA is considered to be involved in liver fibrosis through the regulation of HSCs.

Serum uPA was associated with the fibrosis stage in this study ($p < 0.001$, Figure S1). Recently, Liu et al. indicated that the stage of hepatic fibrosis in HCV-infected patients could be accurately assessed using BioFibroScore, a novel serological panel including uPA, matrix metalloproteinase-9, and beta-2 microglobulin [[25]]. This prompted us to combine other serum fibrotic markers to investigate the prognostic value of serum uPA in the prediction of the fibrotic stage in HCC patients in future studies.

Aside from uPA, our univariate analyses showed that the AFP level, tumor size, vascular invasion, and pathology stage were also significant prognostic factors associated with the OS of HCC patients undergoing curative resection. However, the multivariate analysis demonstrated that only vascular invasion and the pathology stage were independent prognostic factors for OS. This is consistent with the results of previous studies in which tumor-related factors (vascular invasion and histological stage) determined the outcomes of HCC patients undergoing resection [[26]].

Our study had three main limitations. First, only HCC patients undergoing resection were enrolled. Second, this is a retrospective study, and some patients were lost to follow-up after operation. Third, all patients in this cohort were treated at a tertiary medical center, which means that referral bias could not be completely avoided. These data should be validated externally in other regions of the world. Finally, more information from patients with chronic liver disease without HCC, as well as healthy individuals, should be collected for further investigation together, which will be included in our future work.

In summary, we have presented for the first time that the serum uPA level is a clinically relevant biomarker in HCC patients receiving curative resection, with higher expression of uPA being associated with higher mortality. This also highlights the potential utility of uPA as a therapeutic target for improved treatment strategies. A recent study on a uPA inhibitor, SPINK13, provided exciting and promising evidence of an antitumor effect in a mouse model of HCC. Thus, future research should aim at clarifying whether elevated serum uPA may be useful for identifying patients that are likely to derive clinical benefit from a targeted strategy.

References

1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G: **Hepatocellular carcinoma**. *Nat Rev Dis Primers* 2016, **2**:16018.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: **Global cancer statistics, 2012.** *CA Cancer J Clin* 2015, **65**(2):87-108.
3. Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J *et al.*: **Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.** *Oncotarget* 2017, **8**(33):55715-55730.
4. Bruix J, Sherman M, American Association for the Study of Liver D: **Management of hepatocellular carcinoma: an update.** *Hepatology* 2011, **53**(3):1020-1022.
5. Forner A, Llovet JM, Bruix J: **Hepatocellular carcinoma.** *Lancet* 2012, **379**(9822):1245-1255.
6. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: **Evolving role of uPA/uPAR system in human cancers.** *Cancer Treat Rev* 2008, **34**(2):122-136.
7. Ferraris GM, Sidenius N: **Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction.** *Semin Thromb Hemost* 2013, **39**(4):347-355.
8. Mahmood N, Mihalcioiu C, Rabbani SA: **Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.** *Front Oncol* 2018, **8**:24.
9. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer van Gelder ME, Henzen-Logmans SC *et al.*: **The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.** *Cancer Res* 2000, **60**(3):636-643.
10. Ljuca D, Fatusic Z, Iljazovic E, Ahmetovic B: **Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.** *Bosn J Basic Med Sci* 2007, **7**(2):111-116.
11. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J: **Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.** *Cancer Epidemiol Biomarkers Prev* 2011, **20**(4):609-618.
12. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB: **Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.** *J Cancer Res Clin Oncol* 2000, **126**(11):641-646.
13. Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Dano K: **Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.** *J Lab Clin Med* 1988, **111**(1):42-51.
14. Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ *et al.*: **Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.** *Br J Cancer* 2010, **102**(4):731-737.

15. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM: **Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.** *J Clin Oncol* 2007, **25**(4):349-355.
16. Zhang W, Ling D, Tan J, Zhang J, Li L: **Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.** *Oncol Rep* 2013, **29**(2):637-645.
17. Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, De Paoli M, Plebani M, Tulassay Z: **Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.** *BMC Cancer* 2008, **8**:194.
18. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR: **Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.** *Cancer Res* 1993, **53**(8):1788-1793.
19. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: **Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.** *Prostate* 1999, **39**(2):123-129.
20. Herszenyi L, Istvan G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F: **Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.** *Eur J Cancer Prev* 2008, **17**(5):438-445.
21. Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B, Wang C: **Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.** *Pharmacol Res* 2019, **143**:73-85.
22. Lee YA, Wallace MC, Friedman SL: **Pathobiology of liver fibrosis: a translational success story.** *Gut* 2015, **64**(5):830-841.
23. Hernandez-Gea V, Friedman SL: **Pathogenesis of liver fibrosis.** *Annual review of pathology* 2011, **6**:425-456.
24. Leyland H, Gentry J, Arthur MJ, Benyon RC: **The plasminogen-activating system in hepatic stellate cells.** *Hepatology* 1996, **24**(5):1172-1178.
25. Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC *et al*: **A noninvasive diagnosis of hepatic fibrosis by BioFibroScore(R) in chronic hepatitis C patients.** *J Gastroenterol Hepatol* 2018, **33**(1):291-297.
26. He C, Zhou Z, Xiao Z, Wang J: **Treatment strategy for huge hepatocellular carcinoma with intrahepatic metastasis and macrovascular invasion: a case report and literature review.** *J Cancer Res Ther* 2018, **14**(Supplement):S1233-S1236.

Tables

Table 1. Clinicopathological features of 287 HCC patients undergoing curative resection

Patient demographics	
Age (years)	59.6 ± 11.7
Sex (M : F)	232 : 55
AFP (ng/ml)	6122.1 ± 42202.5
Albumin (mg/dl)	3.4 ± 0.6
Total bilirubin (mg/dl)	1.0 ± 2.4
uPA (ng/ml)	1.0 ± 1.4
Tumor size (cm)	4.6 ± 3.5
Liver cirrhosis, n (%)	123 (42.9%)
Hepatitis (B : C : B+C : NBNC)	140 : 85 : 21 : 41
Pathological features	
Vascular invasion (Yes : No)	160 : 127
Tumor differentiation (well : moderate : poor)	38 : 236 : 12
Histological grade (I : II : III : IV)	105 : 129 : 49 : 4

uPA, urokinase-type plasminogen activator

Table 2. Association between serum uPA and clinical characteristics in 287 HCC patients undergoing curative resection

	High uPA (n = 81)	Low uPA (n = 206)	P-value
Age (years)	60.5 ± 12.9	59.2 ± 11.2	0.431
Male gender, n (%)	61 (75.3%)	171 (83.0%)	0.136
Total bilirubin (mg/dl)	0.9 ± 0.7	1.0 ± 2.8	0.804
Albumin (mg/dl)	3.2 ± 0.5	3.5 ± 0.6	<0.001
Platelet <150 x10 ⁹ /L, n (%)	46 (56.8%)	88 (42.7%)	0.032
AFP >200ng/ml, n (%)	24 (29.6%)	42 (20.4%)	0.094
Liver cirrhosis, n (%)	48 (59.3%)	75 (36.4%)	<0.001
Tumor size >5cm, n (%)	24 (29.6%)	64 (31.1%)	0.812
Vascular invasion, n (%)	46 (56.8%)	114 (55.3%)	0.824
Pathology stage III+IV, n (%)	19 (23.5%)	34 (16.5%)	0.172

High uPA: uPA ≥1 ng/ml; low uPA: uPA < 1ng/ml

Table 3. Univariate and multivariate analysis of prognostics factors for overall survival in HCC patients after curative resection

Variable	Comparison	Univariate		Multivariate	
		HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	≥65 vs. <65	1.311 (0.857 - 2.006)	0.212		
Gender	Male vs. Female	0.990 (0.583 - 1.682)	0.971		
Total bilirubin (mg/dl)	Per 1 unit increase	0.986 (0.888 - 1.095)	0.787		
Albumin (mg/dl)	Per 1 unit increase	1.001 (0.692 - 1.447)	0.998		
Platelet ($\times 10^9$ /L)	<150 vs. ≥150	1.028 (0.675 - 1.566)	0.897		
AFP (ng/ml)	≥200 vs. <200	2.012 (1.288 - 3.143)	0.002		
uPA (ng/ml)	≥1 vs. <1	1.968 (1.271 - 3.049)	0.002	1.848 (1.191 - 2.867)	0.006
Liver cirrhosis	Yes vs. No	1.039 (0.680 - 1.588)	0.859		
Tumor size (cm)	≥5 vs. <5	2.402 (1.575 - 3.663)	<0.001		
Vascular invasion	Yes vs. No	3.812 (2.268 - 6.407)	<0.001	2.940 (1.655 - 5.224)	<0.001
Pathology stage	III+IV vs. I+II	4.980 (3.226 - 7.687)	<0.001	3.517 (2.208 - 5.600)	<0.001

Declarations

Disclosure statement: There are no conflicts of interest to disclose for all authors.

Acknowledgments

This study was supported by grants CMRPG8F1671 and CMRPG890161 from Chang Gung Memorial Hospital, Taiwan. We thank the Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank Core Lab (CLRPG810031) for their excellent technical support. Furthermore, we thank Chih-Yun Lin and the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital, for the statistical work.

Author Contributions

Dr. T-HH designed the study, and Dr. M-CT contributed to the writing of this manuscript. The other authors were actively involved in the interpretation of the results, provided critical review of the manuscript, and

contributed to the final decision about the article's content.

Figures





Figure 1

Disease-free survival (A) and overall survival (B) of HCC patients after curative resection stratified by serum uPA.




Figure 2

Overall survival of HCC patients after curative resection stratified by the combination of serum uPA and AFP levels.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS1.docx](#)